Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Grifols

NASDAQ: GRFS ↗$7.34 USD~$5B MCAP

Global plasma-derived medicines group that fractionates human plasma into immunoglobulins, albumin and coagulation therapies, and also supplies diagnostics and hospital products. It operates a large plasma-collection network across the United States, Europe and Canada.

Company Info

Sector:Plasma-Derived Therapeutics
Headquarters:Barcelona, Spain
Founded:1940

Clinical Development Pipeline

Gamunex-C

Target: Polyclonal human IgG
Primary immunodeficiency and neuroimmunology
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Prolastin-C

Target: Alpha-1 proteinase inhibitor
Alpha-1 antitrypsin deficiency
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Xembify

Target: 20% subcutaneous human IgG
Primary humoral immunodeficiency (subcutaneous)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

No recent news updates available for this company.

Leadership Team

Jose Ignacio (Nacho) Abia

Chief Executive Officer (since April 2024)

Thomas Glanzmann

Executive Chairman

Careers & Job Openings

See all open roles

Careers
See posting
Apply Now →